d 3 cell line Search Results


hbmecs d3 cell line  (Merck KGaA)
90
Merck KGaA hbmecs d3 cell line
Hbmecs D3 Cell Line, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+3+cell+line/hbmecs+d3+cell+line/pmc07785856-106-3-7
Average 90 stars, based on 1 article reviews
hbmecs d3 cell line - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hcmec/d3 cell line  (Isca Biochemicals)
90
Isca Biochemicals hcmec/d3 cell line
GLP-1R inhibition does not alter the skin <t>microvascular</t> response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)
Hcmec/D3 Cell Line, supplied by Isca Biochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+3+cell+line/hcmec+d3+cell+line/pmc06677680-152-17-33
Average 90 stars, based on 1 article reviews
hcmec/d3 cell line - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
murine escs (d3 cell line  (Corning Life Sciences)
90
Corning Life Sciences murine escs (d3 cell line
GLP-1R inhibition does not alter the skin <t>microvascular</t> response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)
Murine Escs (D3 Cell Line, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+3+cell+line/murine+escs++d3+cell+line/pmc04459715-188-0-17
Average 90 stars, based on 1 article reviews
murine escs (d3 cell line - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
hcmec/d3 cell line catalog no.: cl-0843  (iCell Gene Therapeutics)
90
iCell Gene Therapeutics hcmec/d3 cell line catalog no.: cl-0843
GLP-1R inhibition does not alter the skin <t>microvascular</t> response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)
Hcmec/D3 Cell Line Catalog No.: Cl 0843, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+3+cell+line/hcmec+d3+cell+line+catalog+no+++cl+0843/pm40189804-75-20-29
Average 90 stars, based on 1 article reviews
hcmec/d3 cell line catalog no.: cl-0843 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
bbb hcmec/d3 cell-line  (Merck KGaA)
90
Merck KGaA bbb hcmec/d3 cell-line
GLP-1R inhibition does not alter the skin <t>microvascular</t> response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)
Bbb Hcmec/D3 Cell Line, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+3+cell+line/bbb+hcmec+d3+cell+line/pmc06950972-205-16-18
Average 90 stars, based on 1 article reviews
bbb hcmec/d3 cell-line - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
name hcmec d3 d3  (Weksler)
86
Weksler name hcmec d3 d3
GLP-1R inhibition does not alter the skin <t>microvascular</t> response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)
Name Hcmec D3 D3, supplied by Weksler, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/d+3+cell+line/cell+d3+hcmec+line/us12622978-855-21-24
Average 86 stars, based on 1 article reviews
name hcmec d3 d3 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


GLP-1R inhibition does not alter the skin microvascular response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)

Journal: Diabetologia

Article Title: Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

doi: 10.1007/s00125-019-4918-x

Figure Lengend Snippet: GLP-1R inhibition does not alter the skin microvascular response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)

Article Snippet: The role of NO in mediating the microvascular actions of GLP-1 analogues was examined in cultured human microvascular endothelial cells (HCMEC/D3 cell line) [ ] by assessing the effects of exenatide (100 pmol/l) (Isca Biochemicals, Exeter, UK) and liraglutide (10 nmol/l) (Isca Biochemicals) on endothelial nitric oxide synthase (eNOS) activation (phosphorylation) and nitrate levels.

Techniques: Inhibition, Saline, Microinjection

Exenatide and liraglutide increase eNOS phosphorylation and nitrate levels. ( a ) eNOS phosphorylation: after initial starvation, human microvascular endothelial cells (HCMEC/D3s) were treated with exenatide and liraglutide for 10 min. Controls were treated with 0.1% BSA medium only. Phosphorylation data were normalised to total eNOS ( n =8). ( b ) Nitrate levels: HCMEC/D3s were treated with exenatide and liraglutide for 24 h ( n =9). Controls were treated with medium only. For both ( a ) and ( b ), data are expressed as percentage of control, with control set at 100%, and are presented as median (25th–75th percentile). * p <0.05, ** p <0.01 vs control, Wilcoxon sign rank test.

Journal: Diabetologia

Article Title: Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

doi: 10.1007/s00125-019-4918-x

Figure Lengend Snippet: Exenatide and liraglutide increase eNOS phosphorylation and nitrate levels. ( a ) eNOS phosphorylation: after initial starvation, human microvascular endothelial cells (HCMEC/D3s) were treated with exenatide and liraglutide for 10 min. Controls were treated with 0.1% BSA medium only. Phosphorylation data were normalised to total eNOS ( n =8). ( b ) Nitrate levels: HCMEC/D3s were treated with exenatide and liraglutide for 24 h ( n =9). Controls were treated with medium only. For both ( a ) and ( b ), data are expressed as percentage of control, with control set at 100%, and are presented as median (25th–75th percentile). * p <0.05, ** p <0.01 vs control, Wilcoxon sign rank test.

Article Snippet: The role of NO in mediating the microvascular actions of GLP-1 analogues was examined in cultured human microvascular endothelial cells (HCMEC/D3 cell line) [ ] by assessing the effects of exenatide (100 pmol/l) (Isca Biochemicals, Exeter, UK) and liraglutide (10 nmol/l) (Isca Biochemicals) on endothelial nitric oxide synthase (eNOS) activation (phosphorylation) and nitrate levels.

Techniques: Phospho-proteomics, Control